

## Review Article

# A systematic review of potential anticancer activities of *Muntingia calabura* L. With a focus on cellular and molecular mechanisms

Muna Hamoud Alseaghi<sup>1</sup>, Melati Khalid<sup>1\*</sup>, Razana Mohd Ali<sup>1</sup>, Muhammad Nazrul Hakim Hakim<sup>1</sup>, Zainul Amiruddin Zakaria<sup>1</sup>,

<sup>1</sup>Dept. of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

## Abstract

Medicinal plants have been extensively explored for their chemopreventive and antiproliferative properties. Among these, *Muntingia calabura* has emerged as a promising candidate due to its ability to modulate various signaling pathways involved in cancer progression and suppression. This includes interactions with multiple cell signaling molecules that regulate cancer formation and development. This review aims to critically evaluate the anticancer properties of *M. calabura* across different cancer types. A systematic literature search was performed across major scientific databases, including ScienceDirect, PubMed, and Scopus. Studies were selected based on predefined inclusion criteria using the keywords "Muntingia calabura", "M. calabura", "anticancer" and "cancer." A total of 13 studies met the eligibility criteria and were analyzed for this review. Evidence from the reviewed studies highlights the anticancer effects of *M. calabura* extracts, which include inhibition of inflammatory and apoptotic pathways. The modulation of dysregulated signaling cascades, such as the LOX, XO, and RAF1 pathways, was shown to contribute significantly to its anticancer activity. The findings support the potential application of *M. calabura* and its phytochemical constituents in cancer prevention and therapy. However, further in-depth studies are necessary to identify its bioactive compounds and elucidate the mechanisms underlying its anticancer effects for clinical translation.

**Keywords:** *Muntingia calabura*, Anticancer, Phytochemicals, Flavonoids

**Received:** 14-03-2025; **Accepted:** 06-05-2025; **Available Online:** 09-06-2025

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Medicinal plants have long played a significant role in treating various human diseases, including cancer. Several plant-derived compounds, such as Vincristine, Vinblastine, and Paclitaxel, have been successfully developed into anticancer drugs.<sup>1-2</sup> A major challenge in cancer therapy is to develop treatments that selectively target cancer cells while minimizing harm to healthy tissues and reducing drug resistance.<sup>3</sup> The use of plant-based compounds as alternative anticancer agents has gained increasing interest, with *Muntingia calabura* L. (Jamaican cherry) emerging as a potential candidate.<sup>4-5</sup>

*M. calabura*, the only species in its genus within the Elaeocarpaceae family, is a fast-growing tree native to tropical America and widely cultivated in Southeast Asia, including Malaysia, Indonesia, and the Philippines.<sup>6</sup> In

Malaysia, *M. calabura*, locally known as "Kerkup siam", is commonly cultivated as a roadside tree.<sup>7</sup> The tree typically grows between 7.5 and 12 meters in height, with horizontally spreading branches, serrated leaves, small white flowers, and spherical fruits that ripen from green to red (**Figure 1**).<sup>8-9</sup> Various parts of the plant, including the leaves, stems, fruits, and roots, have been traditionally used to treat ailments such as headaches, fever, stomach pain, and liver infections.<sup>10-12</sup> Additionally, the fruits, leaves, roots, and bark of *M. calabura* have demonstrated pharmacological properties, including antioxidant, anti-inflammatory, antimicrobial, gastroprotective, and hepatoprotective effects.<sup>13-15</sup>

*M. calabura* is a rich source of essential macronutrients, including carbohydrates, proteins, and lipids, as well as micronutrients such as calcium, iron, and phosphorus.<sup>16</sup> More importantly, it contains a variety of bioactive compounds, particularly flavonoids (e.g., quercetin, kaempferol),

\*Corresponding author: Melati Khalid  
Email: [gs64321@student.upm.edu.my](mailto:gs64321@student.upm.edu.my)

phenolic acids (e.g., gallic acid, ferulic acid), tannins (e.g., ellagic acid), and triterpenoids (e.g., ursolic acid, oleanolic acid).<sup>17-21</sup> These compounds, predominantly concentrated in the leaves, exhibit significant antioxidant, anti-inflammatory, antimicrobial, and anticancer properties.<sup>22-24</sup>

Several studies have investigated the safety profile of *M. calabura* extracts. Acute toxicity studies in animal models indicate that oral administration of the plant's methanol and ethanol extracts is well tolerated at doses up to 5000 mg/kg, with no observed toxic effects.<sup>25</sup> Additionally, no signs of toxicity or mortality were reported in rats treated with ethanol and crude extracts at doses as high as 15,000 mg/kg.<sup>26</sup>

Further evidence from a 90-day sub-chronic toxicity study demonstrated no significant adverse effects in rats receiving methanol extracts at doses of 50, 250, and 500 mg/kg.<sup>27</sup> Histopathological, hematological, and biochemical analyses confirmed that *M. calabura* extracts do not disrupt normal physiological functions. These findings suggest that *M. calabura* is generally safe for consumption, reinforcing its potential as a therapeutic agent.

Despite its diverse medicinal applications, there is a lack of comprehensive reviews assessing *M. calabura*'s potential as an anticancer agent. This review aims to systematically examine the available evidence on its anticancer properties and underlying mechanisms.

## 2. Materials and Methods

The present systematic review was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria.<sup>28</sup> [Studies were selected from multiple electronic databases (Scopus, PubMed, Science Direct, Google Scholar, and EBSCO) up to July 2023. The search strategy employed the keywords: ‘*Muntingia calabura*’ AND ‘*M. calabura*’ AND ‘cancer’ AND ‘anticancer’ AND ‘*in vivo*’ AND ‘*in vitro*’.

Inclusion criteria focused on experimental research both *in vivo* and *in vitro*, evaluating the anticancer potential of *M.*

*calabura* in any animal model and/or cancer cell line. Unrelated papers were excluded based on titles and abstracts, with two independent researchers conducting the review to minimize bias. Review papers, meta-analyses, book chapters, conference abstracts, clinical trials, and non-English language materials were excluded. In total, 57 reports were excluded due to duplicate findings, 27 due to article type, and 10 for being review articles, leaving 50 studies. From these, 33 were eliminated for focusing on other pharmacological effects, and 5 for addressing phytochemicals not derived from *M. calabura*. Ultimately, 13 research papers were included, as depicted in the flowchart (**Figure 2**).

## 3. Results and Discussion

Out of the final 13 articles, 10 focused on in-vitro studies using cancer cell lines, while the remaining three utilized in-vivo animal models. The following section summarizes the anticancer properties of *M. calabura*, as outlined in (**Table 1** and **Table 2**)

The earliest in vitro study (1991) assessed 12 flavonoids from *M. calabura* roots for cytotoxicity against P-388 cells and selectivity towards eight human cancer cell lines. Flavans (compounds 1–7) exhibited stronger cytotoxic activity than flavones (compounds 8, 10, and 12), with ED<sub>50</sub> values ranging from 2–16.7 µg/mL against BC1, HT-1080, Lul, Me12, Col2, KB, KB-V, and P-388.<sup>29</sup> Several compounds demonstrated selective activity against Me12 and KB cells, while compounds 3, 9, and 11 showed broader toxicity. A follow-up study confirmed that 2',4'-dihydroxychalcone and chrysin displayed significant cytotoxicity against multiple cancer cell lines (ED<sub>50</sub>: 0.7–20 µg/mL), while galangin 3,7-dimethyl ether was selective for P-388 cells.<sup>30</sup> These findings highlight the potential of *M. calabura* flavonoids in anticancer drug discovery. Furthermore, flavonoid extracted from *M. calabura* leaves demonstrated chemopreventive activity, with an IC<sub>50</sub> values exceeding 20 µg/mL against mouse Hepa 1c1c7 cells. This suggests that the compounds isolated from *M. calabura* provide a protective effect by mitigating the toxic impact of Quinone reductase.<sup>31</sup>

**Table 1:** Potential anticancer properties and related mechanism of action of *M. calabura* based on *in vitro* stud.

| Reference                   | Cancer type | Cell line   | lant part       | Dose and duration                     | Anticancer effects                         | Mechanisms |
|-----------------------------|-------------|---|-----------------|---------------------------------------|--|------------|
| Kaneda et al. <sup>29</sup> | Various     | BC-1, HT-1080, Lul, Me12, CO12, KB, KB-V, and P-338 | Root            | 20.0, 4.0, 0.8, 0.16, and 0.032 µg/mL | ↑Cytotoxicity effect                       | NR         |
| Nshimo et al. <sup>30</sup> | Various     | BC-1, CO12, HT-1080KB, KB-V1, Lul, Me12, and P-388  | Stem and leaves | NR                                    | ↑Cytotoxicity effect                       | NR         |
| Su et al. <sup>31)</sup>    | Liver       | Hepa 1c1c7  | Leaves          | NR                                    | ↑Quinone reductase<br>↑Cytotoxicity effect | NR         |

|                              |           |   |        |  |   |  |
|------------------------------|-----------|---|--------|--|---|--|
| Chen et al. <sup>32</sup>    | Various   | P-388, a549, and HT-29                                | Leaves | NR                                     | ↑Cytotoxicity effect  | NR   |
| Chen et al. <sup>33</sup>    | Colon     | HT-29 and P-388                                       | Leaves | NR                                     | ↑Cytotoxicity effect  | NR   |
| Zakaria et al. <sup>34</sup> | Various   | 3T3, MCF-7, HeLa, HT-29, HL-60, K-562, and MDA-MB-231 | Leaves | 100-12.5 µg/mL for 72 hours            | ↑Cytotoxicity effect<br>↑Antiproliferative effect                                   | ↑ROS   |
| Sufian et al. <sup>35</sup>  | Various   | MCF-7, HL60, HCT116, and WRL68                        | Leaves | 0.01 to 100 mg/mL for 72 hours         | ↑Cytotoxicity effect  | NR   |
| Zakaria et al. <sup>36</sup> | Colon     | HT-29   | Leaves | 30, 60 and 90 µg/mL for 72 hours       | ↑Antioxidant activity<br>↑Antiproliferative activity<br>↑Anti-inflammatory activity | ↓OX/LOX  |
| Lin et al. <sup>37</sup>     | Liver     | HepG2   | Fruit  | 25, 50 or 100 µg/mL                    | ↓Cell viability   | ↓VEGF<br>↓RAF1/MEK1/2/ERK1/2, and JAK2/STAT3<br>↓PI3K/AKT/mTOR |
| Kumar et al. <sup>38</sup>   | Laryngeal | Hep2  | Fruit  | 20, 50, 70, and 100 µg/mL for 24 hours | ↑Cytotoxicity effect<br>↑Apoptosis effect<br>↓Cell proliferation                    | ↑G2 phase arrest   |

**Notes:** The symbols "↑" and "↓" represent an increase and decrease in specific anticancer activities, respectively. "NR" stand for not reported. VEGF: Vascular endothelial growth factor; 3T3: Normal mouse fibroblast; MCF-7: Oestrogen-dependent human breast adenocarcinoma; HeLa: Human cervical adenocarcinoma; HT-29: Human colon cancer; HL-60: Acute promyelocytic leukaemia; K-562: Chronic myelogenous leukaemia; MDA-MB-231: Human breast carcinoma; HepG2: Hepatocellular carcinoma; RAF1: Serine/threonine kinase; MEK1/2: Mitogen-activated protein kinase 1/2; ERK1/2: Extracellular signal-regulated kinase 1/2; JAK2: Janus kinase 2; STAT3: Signal transducers and activators of transcription 3; ROS: Reactive oxygen species.


**Table 2.** Potential anticancer properties and related mechanisms of action of *M. calabura* based on *in vivo* studies.

| Reference                  | Cancer type | Animal model             | Plant part | Dose and duration                  | Anticancer effects  | Mechanisms  |
|----------------------------|-------------|--------------------------|------------|------------------------------------|---|---|
| Nasir et al. <sup>39</sup> | Colorectal  | Male Sprague-Dawley rats | Leaves     | 50, 250, and 500 mg/kg for 8 weeks | ↓ACF number<br>↓Oxidative activity<br>↑Antioxidant activity       | ↑SOD, CAT, and GSH<br>↓MDA  |
| Jisha et al. <sup>40</sup> | Colorectal  | Female Wistar rats       | Leaves     | 20 and 50 mg/kg for 15 weeks       | ↑Apoptosis effect<br>↓Cell proliferation<br>↑Antioxidant activity | ↓NF-κB and COX-2<br>↑SOD, CAT, & GR<br>↓MDA and ROS<br>↑RBC, Hb, and Hct<br>↓WBC<br>↓AST, ALT, ALP, and total bilirubin<br>↑Connexin-43, p53, Caspases-3, and Caspase-9 |
| Jisha et al. <sup>41</sup> | Colorectal  | Female Wistar rats       | Leaves     | 100 and 200 mg/kg for 15 weeks     | ↑Antioxidant activity   | ↑SOD, CAT, and GR<br>↓MDA and ROS<br>↑Hb<br>↓WBC & ESR<br>↓AST, ALT, ALP and total bilirubin  |

**Notes:** The symbols "↑" and "↓" represent an increase and decrease in specific anticancer activities, respectively. SOD: Superoxide dismutase; CAT: Catalase; GSH: Glutathione; GR: Glutathione reductase; MDA: Malondialdehyde; ACF: Aberrant crypt foci; Hb: Hemoglobin; WBC: White blood cell; ESR: Erythrocyte sedimentation rate; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; NF-KB: Nuclear factor kappa B; COX-2: Cyclooxygenase-2.



**Figure 1:** The various parts of *M. calabura*. (a) The *M. calabura* tree. (b) The leaves of *M. calabura*. (c) The flower of *M. calabura*. (d) The fruit of *M. calabura* (Adapted from NParks, 2024).



**Figure 2:** The flow chart of the PRISMA selection procedure for the included studies.

Subsequent research expanded cytotoxicity testing to P-388, A549, and HT-29 cells. Among the 15 isolated compounds, seven compounds (8-hydroxy-7, 3', 4', 5'-tetramethoxyflavone (1), 8, 4'-dihydroxy-7, 3', 5'-trimethoxyflavone (2), 3, 5-Dihydroxy-6, 7-dimethoxyflavone (5), (2S)-5'-Hydroxy-7, 8, 3', 4'-tetramethoxyflavan (6), Syringic acid (10), Vanillic acid (11), and 3-hydroxy-1-(3, 5-dimethoxy-4-hydroxyphenyl) propan-1 (12)) demonstrated cytotoxic activity against P-388 cells ( $ED_{50}$ : 3.27–15.62  $\mu\text{g/mL}$ ), while only one compound showed significant effects on HT-29 and A549 cells.<sup>32</sup> Further analysis of 20 isolates identified four flavonoids

((2S)-5'-hydroxy-7, 3', 4'-trimethoxyflavanone, 4'-hydroxy-7-methoxyflavanone, 2', 4'-dihydroxychalcone, and 2', 4'-dihydroxy-3'-methoxychalcone) with notable cytotoxicity ( $IC_{50} < 4 \mu\text{g/mL}$ ) against P-388 and/or HT-29 cells.<sup>33</sup>

In another study, the antiproliferative activity of chloroform, aqueous, and methanol extracts of *M. calabura* was tested against MCF-7, HeLa, HL-60, K-562, MDA-MB-231, and 3T3 cells using the MTT assay (12.5–100  $\mu\text{g/mL}$ ) [34]. None of the extracts inhibited MDA-MB-231 or 3T3 cell proliferation, suggesting selective cytotoxicity towards cancer cells. The aqueous, methanol, and chloroform extracts exhibited antiproliferative effects against MCF-7 ( $IC_{50}$ : 18–98  $\mu\text{g/mL}$ ), HeLa ( $IC_{50}$ : 23–52  $\mu\text{g/mL}$ ), K-562 ( $IC_{50}$ : 18–42  $\mu\text{g/mL}$ ), HT-29 ( $IC_{50}$ : 16–46  $\mu\text{g/mL}$ ), and HL-60 ( $IC_{50}$ : 7–29  $\mu\text{g/mL}$ ). These effects are likely due to the plant's antioxidant properties and high polyphenolic content, with methanol extracts showing the strongest antioxidant activity.

A study on the cytotoxicity of *M. calabura* methanolic (MeOH) extract and its partitions (petroleum ether (PEE), ethyl acetate (EAE), and aqueous (AE)) against MCF-7, HL-60, HCT116, and WRL68 found that MeOH showed moderate cytotoxicity against HL-60 and HCT116 ( $IC_{50}$ : 30.90 and 61.29  $\mu\text{g/mL}$ , respectively) [35]. PEE and EAE exhibited  $IC_{50}$  values of 29.46 and 47.19  $\mu\text{g/mL}$  (PEE) and 17.26 and 58.44  $\mu\text{g/mL}$  (EAE). None of the partitions showed substantial cytotoxicity against MCF-7, and AE lacked cytotoxicity against all tested cell lines ( $IC_{50} > 100 \mu\text{g/mL}$ ). EAE demonstrated selectivity toward HL-60 ( $SI=4.54$ ) compared to WRL68, suggesting its potential in cancer therapy. Further fractionation of EAE identified 7 major fractions, of which F5 was the most active ( $IC_{50}$ : 3.98, 34.85, and 32.29  $\mu\text{g/mL}$  for HL60, MCF7, and WRL68). Four bioactive compounds were isolated, including two novel flavones (5,7-dihydroxy-3,8-dimethoxyflavone and 5-hydroxy-3,7-dimethoxyflavone). The other 2 Compounds have been reported previously to possess various biological activities such as antimicrobial, cytotoxicity, antioxidant, and anti-inflammatory activity.

The ethyl acetate partition (EAP) showed potent antiproliferative activity against HT-29 ( $IC_{50}$ : 58  $\mu\text{g/mL}$ ) while sparing normal 3T3 cells. It also exhibited high inhibition of LOX (>95%) and XO (>70%), indicating anti-inflammatory potential<sup>36</sup>

*M. calabura* fruit ethanolic extract (MFEE) reduced the vascular endothelial growth factor (VEGF) expression in nickel-stimulated HepG2 cells in a dose-dependent manner, resembling the effect of gallic acid.<sup>37</sup> MFEE also downregulated RAF1, MEK1/2, ERK1/2, PI3K, JAK2, STAT3, AKT, and mTOR while sparing P-38 and P-JNK1/2 expression, highlighting its anticancer potential. This was strengthened by the similar result presented by gallic acid, the major phenolic compound in MFEE, which was used for comparison. VEGF plays a crucial role in cancer promotion and angiogenesis, therefore, the down-regulation of VEGF

expression and the reduction of neovascularization is one of the target effects of cancer treatment.

Gold nanoparticles synthesized with *M. calabura* extract (MC-AuNPs) selectively induced apoptosis in Hep2 cells, causing membrane disruption, nuclear alteration, and G2-phase cell cycle arrest.<sup>38</sup>

Transitioning from *in vitro* to *in vivo* investigations, the chemopreventive potential of *M. calabura* against colon cancer in rats was explored. The study showed a reduction in aberrant crypt foci (ACF) formation, indicating a potential role for *M. calabura* extracts in protecting against colon carcinogenesis.<sup>39</sup> The reduction in ACF number is attributed to the antioxidant activity of MEMC. The findings showed that MEMC treatment increased antioxidants levels such as SOD, CAT, and GSH while decreasing the level of oxidative stress markers like MDA in the colon tissues of rats. Additionally, HPLC analysis of MEMC identified various phenolic compounds, including gallic acid, catechin, epicatechin, ferulic acid, and pinocembrin, which are known to possess antioxidant, anti-inflammatory, and anticancer properties.

Similarly, the anticancer effects of the ethyl-acetate fraction of *M. calabura* (EFMC) revealed improvements in antioxidant levels, modulation of inflammatory markers, and regulation of apoptotic genes. These changes may be attributed to its inhibition of the NF- $\kappa$ B pathway, which plays a crucial role in CRC development.<sup>40-41</sup> Additionally, EFMC was found to downregulate the expression of genes such as COX-2, TNF- $\alpha$ , p53, IL-6, Casp-9, Casp-3 and Connex-43, all of which are involved in CRC development. RT-PCR analysis revealed that DMH treatment downregulated Connexin-43, Caspases-3, p53 and Caspase-9 gene expression, while EFMC significantly increased expressions. These findings were supported by western blot analysis, which showed increased expression of COX-2 and NF- $\kappa$ B in the DMH group, while EFMC treatment caused a significant reduction in the expression of COX-2 and NF- $\kappa$ B.

Overall, the ant proliferative and cytotoxic properties of *M. calabura* extracts, compounds, and partitions against various cancer cells are primarily attributed to their rich phytochemical composition. Studies have identified bioactive constituents, including phenolic acids and flavonoids, which likely act synergistically to exert anticancer effects.

#### 4. Conclusion

In conclusion, the collective findings from *in vitro* and *in vivo* studies underscore the potential of *Muntingia calabura* as a promising source of anticancer agents. This review highlights its selective cytotoxicity against multiple cancer cell lines and its chemopreventive effects in animal models. Given its affordability, long history of use, widespread availability, and diverse pharmacological activities, *M. calabura* holds

promise as an anticancer and chemopreventive agent. Studies have demonstrated its effects against a range of cancers, including breast, colon, laryngeal, lung, prostate, hepatocellular carcinoma, melanoma, and leukemia, with potential applications beyond these types.

The observed selective cytotoxicity, alongside its modulation of critical cellular pathways such as NF- $\kappa$ B/IL-6/STAT3, IKK/NF- $\kappa$ B, PI3K/Akt/mTOR, ERK, Bcl-2, and VEGF, suggests that *M. calabura* could play a significant role in future anticancer strategies. However, since most existing evidence is derived from *in vitro* studies, with limited *in vivo* or clinical data, further research involving animal models and randomized clinical trials is crucial. To fully harness its therapeutic potential for cancer treatment and prevention, deeper investigations into its mechanisms and clinical applications are essential.

#### 5. Acknowledgement

This work was supported by the Fundamental Research Grant Scheme [FRGS/1/2018/SKK10/UPM/02/4] and the Geran Putra Berimpak [UPM/800-3/3/1/GPB/2020/9685000].

#### 6. Conflict of Interest

The authors declare that there is no conflict of interests regarding the publication of this manuscript.

#### 7. Source of Funding

None.

#### 8. Conflict of Interest

None.

#### References

1. Arumugam, S., Parveen, H., Kalathil, A., Alex, A. S., Sellamuthu, V., & Ganesan, B. (2015). Colon Cancer and Herbal Medications: Preclinical Aspects of Dmh and 5-Fu in Wistar Albino Rats-a Review. *Eur J Biomed Pharma Sci*. [www.ejbps.com](http://www.ejbps.com), 2015;8,272.
2. Dehelean, C. A., Marcovici, I., Soica, C., Mioc, M., Coricovac, D., Iurciuc, S., Cretu, O. M., & Pinzaru, I. (2021). Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy. *Molecules* 2021;26(4):1109.
3. Huang M, Lu JJ, Ding J. Natural Products in Cancer Therapy: Past, Present and Future. *Nat Prod Biopros*, 2021;11(1):5–13.
4. Aiello P, Sharghi M, Mansourkhani SM, Ardekan AP, Jouybari L., Daraei N. Medicinal Plants in the Prevention and Treatment of Colon Cancer. *Oxidative Medicine and Cellular Longevity*, 2019, 2075614.
5. Preethi K. Phytochemistry of *Muntingia calabura* L. 1st Edi Fruits. In medicinal plants. 261-8.
6. Mahmood N.D., Nasir N.L.M., Rofiee MS, Tohid S.F.M., Ching SM, Teh LK. *Muntingia calabura*: A review of its traditional uses, chemical properties, and pharmacological observations. *Pharma Biol*, 2014;52(12):1598–623.
7. Zakaria, Amiruddin Z, Mustapha S., Sulaiman M.R., Jais M, Somchit M.N., Abdullah F.C. The antinociceptive action of aqueous extract from *Muntingia calabura* leaves: The role of opioid receptors. *Med Princip Pract*. 2007;16(2):130–6.

8. Ansori ANM, Kharisma VD, Solikhah TI, Medicinal properties of muntingia calabura L.: A review. *Res J Pharm Technol*, 2021;14(8):4509-12.
9. Kehinde BA, Nayik GA, Rafiq S. Muntingia calabura. Antioxidants in Fruits: Properties and Health Benefits, 251–70.
10. Upadhye M, Kuchekar M, Pujari R, Kadam S, Gunjal P. Muntingia calabura: A comprehensive review. *J Pharm Biol Sci*, 2022;9(2):81–7.
11. Sarojini S, Mounika B. Muntingia Calabura (Jamaica Cherry): An Overview. *Pharma Tutor*, 2018;6(11):1–9.
12. Saud B, Geetha KM, Dubey S, Singh PK, Shrivastava S, Singh D. Traditional, current and prospective therapeutic uses of Muntingia calabura: a comprehensive literature review. *Res J Med Plant*. 2023;17(1):9-22.
13. Chaudhari RN, Jain AK, Chatap VK. An Overview on Phytochemistry, Pharmacology, and Traditional aspects of Muntingia calabura. *Res J Pharm Technol*. 2022;15(6):2814–20.
14. Nirmala M, Priya R, Shankar T, Malarvizhi A. Medicinal Values of Muntingia calabura Leaves. *Pharmacol Benefits Nat Prod*, 2018;14(114):238-53.
15. Firdausi L, Indahsari N, FadillahWati N, Saryono S. Utilization of Kersen Leaves (Muntingia calabura L.) for Diabetes Mellitus Patients: A Systematic Review. *AIP Conference Proceedings*. 2023;2586(1):14-5.
16. Khalwati Afdhaliya N, Indarto D, Wasita B. Chemical Analysis of Iron, Vitamin C, Tannins and Total Flavonoids in Ethanol Extract of Jamaican Cherries Fruits (Muntingia calabura L) for Development of Antianemia. 2021; p.1-5.
17. Tungmunthum D, Thongboonyou A, Pholboon A, Yangsabai A. Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview. *Medicines*, 2018;5(3):93.
18. Mastuki SN, Faudzi SMM, Ismail N, Saad N. Muntingia calabura: Chemical Composition, Bioactive Component and Traditional Uses. Wild Fruits: Composition, *Nut Value Prod*, 2019;549–64.
19. Gurning K, Simanjuntak HA, Purba H, Situmorang RFR, Barus L, Silaban S. Determination of Total Tannins and Antibacterial Activities Ethanol Extraction Seri (Muntingia calabura L.) Leaves. *J Physics: Conference Series*, 2021;1811(1):012121.
20. Nasution F, Theanhom AA, Unpaprom Y, Ramaraj R, Manmai N, Chumpookam J. Muntingia calabura fruits as sources of bioactive compounds and fermentative ethanol production. *Biomass Conversion and Biorefinery*, 2024;14(4):4703–14.
21. Pereira GA, Arruda HS, de Moraes DR, Eberlin MN, Pastore GM. Carbohydrates, volatile and phenolic compounds composition, and antioxidant activity of calabura (Muntingia calabura L.) fruit. *Food Res Int*, 2018;108:264–73.
22. Seixas DP, Palermo FH, Rodrigues TM. Leaf and stem anatomical traits of Muntingia calabura L. (Muntingiaceae) emphasizing the production sites of bioactive compounds. *Flora*, 2021;278:151802.
23. Taslim NA, Sutisna N, Nurkolis F, Qhabibi FR, Kurniawan R, Mayulu N. Dietary supplementation of Muntingia calabura leaves ameliorates reactive oxygen species and malondialdehyde levels: clinical study on alloxan-induced hyperglycemic rats. *Clin Nutr Open Sci*. 2023;48:87-96.
24. Rifa'i M, Wahyuningsih MD, Lestari ND, Ibrahim M, Soewondo A, Tsuboi H. Bioactivity of cherry (Muntingia calabura L.) leaves extract for il-6 production and nf-kb activity in hyperglycemic balb/c mice. *Med Plants-Int J Phytomed Related Ind*, 2018;10(4):305-11.
25. Ibrahim IAA, Abdulla MA, Abdelwahab SI, Al-Bayaty F, Majid N.A. Leaves extract of Muntingia calabura protects against gastric ulcer induced by ethanol in Sprague-dawley rats. *Clin Experin Pharmacol*. 2012;5:59-61.
26. Siriarchavatana P, Poonsiri C, Khayungamawee A, Laovithayangoon S. Acute Oral Toxicity Test of Muntingia Calabura L. Extract In Rats. *Digital Car Chula*. 2012;35:56-8.
27. Nasir NLM, Kamsani NE, Mohtarrudin N, Tohid SFM, Zakaria, Z.A. Safety evaluation of orally-administered methanol extract of Muntingia calabura Linn. leaves: A sub-chronic toxicity study in Sprague Dawley rats. *Pak J Pharma Sci*, 2020;33(5):2009–16.
28. Page M. J., McKenzie J.E., Bossuyt P.M., Boutron I, Hoffmann T. C, Mulrow C.D The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* (Clinical Research Ed.), 2021; 372.
29. Kaneda, N., Pezzuto, J. M., Soejarto, D. D., Kinghorn, A. D., Farnsworth, N. R., Santisuk, T., Tuchinda, P., Udchachon, J, Reutrakul V. Plant anticancer agents, XLVIII. New cytotoxic flavonoids from Muntingia calabura roots. *J Nat Prod*. 1991;54(1):196–206.
30. Nshimo C, Pezzuto JM, Kinghorn AD, Farnsworth NR. (1993). Cytotoxic constituents of muntingia calabura leaves and stems collected in Thailand. *Pharma Biol*. 1993; 31(1), 77–81.
31. Su BN, Park EJ, Vigo JS, Graham JG, Cabieses F, Fong HHS. Activity-guided isolation of the chemical constituents of Muntingia calabura using a quinone reductase induction assay. *Phytochemistry*, 2003;63(3):335–41.
32. Chen JJ, Lin RW, Duh CY, Huang HY, Chen I.S. Flavones and cytotoxic constituents from the stem bark of Muntingia calabura. *J Chin Chem Soc*. 2004;51(3):665–70.
33. Chen, J. J., Lee, H. H., Duh, C.Y., Chen, I. S. Cytotoxic chalcones and flavonoids from the leaves of Muntingia calabura. *Planta Med*, 2005;71(10), 970–3.
34. Zakaria ZA, Mohamed AM., Jamil, N. S. M., Rofee, M. S., Hussain, M. K., Sulaiman, M. R., Teh, L. K., Salleh M. Z. In vitro antiproliferative and antioxidant activities of the extracts of Muntingia Calabura leaves. *Am J Chin Med*. 2011;39(1):183–200.
35. Sufian AS, Ramasamy K, Ahmat N, Zakaria ZA, Yusof MIM. Isolation and identification of antibacterial and cytotoxic compounds from the leaves of Muntingia Calabura L. *J Ethnopharmacol*, 2013;146(1):198–204.
36. Zakaria, Amirudin Z, Nasir MD, Kamsani NL, NE, Khaza H, Sulistyorini L. Ethyl acetate partition obtained from the methanol extract of Muntingia calabura leaf exerts effective in vitro antiproliferative activity against the HT-29 colon cancer. *Boletín Latinoamericano y Del Caribe de Plantas Med Aromát*, 2022;21(5):654-70.
37. Lin JT, Chang YY, Chen YC, Kuo LC, Yang DJ. Protective effect and mechanism of Muntingia calabura Linn. fruit ethanolic extract against vascular endothelial growth factor production in nickel-stimulated hepatocellular carcinoma cells. *J Func Foods*. 2018;47, 343–9.
38. Kumar PS, Jeyalatha MV, Malathi J, Ignacimuthu S. Anticancer effects of one-pot synthesized biogenic gold nanoparticles (Mc-AuNps) against laryngeal carcinoma. *J Drug Deliv Sci Technol*, 2018;44(18):118–28.
39. Nasir NLM., Kamsani NE, Mohtarrudin N, Othman F, Tohid SFM, Zakaria ZA. Anticarcinogenic activity of Muntingia calabura leaves methanol extract against the azoxymethane-induced colon cancer in rats involved modulation of the colonic antioxidant system partly by flavonoids. *Pharma Biol*, 2017;55(1):2102.
40. Jisha N, Vysakh A, Vijeesh V, Anand PS, Latha MS. Methanolic Extract of Muntingia Calabura L. Mitigates 1,2-Dimethyl Hydrazine Induced Colon Carcinogenesis in Wistar Rats. *Nutr Cancer*, 2021;73(11–12):2363–75.
41. Jisha N, Vysakh A, Vijeesh V, Latha MS. (2020). Ethyl acetate fraction of Muntingia calabura L. exerts anti-colorectal cancer potential via regulating apoptotic and inflammatory pathways. *J Ethnopharmacol*. 2010;261:113064.

**Cite this article:** Alseaghi MH, Khalid M, Ali RM, Hakim MZ, Zakaria ZA. A systematic review of potential anticancer activities of Muntingia calabura L. With a focus on cellular and molecular mechanisms. *Journal of Pharmaceutical Biological Science*. 2025;13(1):20-25.